To prevent the effects of alpha-synuclein in the brain, a tiny particle of cerium oxide is used which is compound with antioxidant properties a representing a new therapeutic treatment for the Parkinson’s disease. Several factors are there that contributes to Parkinson’s disease progression, including the accumulation of alpha-synuclein proteins inside nerve cells and the formation of toxic protein aggregates called Lewy bodies. Efforts have been made by the researchers to develop pharmacological approaches capable of fighting Parkinson’s disease, but no effective solution has been found.
Most pharmacological compounds are non- specific, resulting in severe side effects. Most of the available compounds are unable to cross the blood-brain barrier which is a semipermeable membrane protecting the brain and are not able to reach the nerve cells affected by Parkinson’s.
The utilization of nanoparticles loaded with an active agent has shown some promise in overcoming these limitations. The surface of these particles contains small markers that help them to pass through the blood-brain barrier and gain access to the central nervous system, specifically anchoring to the intended target cells and releasing their active pharmacological agent.
The utilization of nanoparticles to target abnormal alpha-synuclein proteins is being proposed by the researchers. To find the most appropriate nanoparticle, the computer-based analysis is made to all known mechanisms concerning alpha-synuclein inclusion in Parkinson’s.
The three different nanoparticles include the gold nanoparticles, graphene, and the super-paramagnetic iron-oxide nanoparticles are used to prevent fibrils formation and cerium oxide nanoparticles as due to their antioxidant and anti-apoptotic properties they have shown neuroprotective activity. The gold nanoparticles are used as it prevent alpha-synuclein aggregation
Their analysis was based on compiled information about drug design and effects, disease diagnosis and features, as well as molecular target interactions and systems biology data.
The researchers have found that cerium oxide nanoparticles upon being analyzed using the computer-based stimulation methods and protein modeling, had a greater affinity toward alpha-synuclein while sustaining good stability and overall response. The analysis discloses that cerium oxide prevents the aggregation of alpha-synuclein by promoting the activation of dopamine receptors and the regulation of signaling pathways and genes important in Parkinson’s disease. The researchers have proposed that the cerium oxide nanoparticles is a potential inhibitor of alpha-synuclein can be used as a nano-drug against Parkinson’s disease on the basis of the preclinical results.
Comments
Post a Comment